Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
NEW YORK, Oct. 09, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Endo International plc ("Endo ") (NASDAQ:ENDP) securities between November 30, 2012 and July 6, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/endo-international-plc?wire=3. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you suffered a loss in Endo you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/endo-international-plc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
